News - Research, Gilead Sciences

Filter

Current filters:

ResearchGilead Sciences

Popular Filters

1 to 25 of 38 results

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

Encouraging results with Gilead’s combo ranolazine and dronedarone in AFB

Encouraging results with Gilead’s combo ranolazine and dronedarone in AFB

12-05-2014

US antiviral specialist Gilead Sciences has released positive results from HARMONY, a randomized, double-blind,…

BiotechnologyCardio-vasculardronedaroneGilead SciencesRanolazineResearch

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

Janssen releases Phase II data for combination of simeprevir and sofosbuvir

Janssen releases Phase II data for combination of simeprevir and sofosbuvir

15-04-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has announced positive new…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHealth Medical PharmaHepatitisJanssen BiotechProtease inhibitorsResearchsimeprevirsofosbuvirUSA

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

10-04-2014

US antivirals major Gilead Sciences today announced positive findings from an open-label clinical trial…

Anti-viralsBiotechnologyGilead SciencesResearchSovaldi

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

16-01-2014

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

09-12-2013

The 55th American Society of Hematology (ASH) meeting began in New Orleans on Saturday with a host of…

Gilead SciencesNorth AmericaNovartisPharmaceuticalResearchRocheTakeda Pharmaceuticals

Gilead's HIV combo drug Stribild shows viral suppression after three years

Gilead's HIV combo drug Stribild shows viral suppression after three years

16-10-2013

Gilead Sciences has announced results from two Phase III studies for its combination drug Stribild in…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaResearchStribild

Gilead to stop Ph III Study 116 of idelalisib early on DMC recommendation

10-10-2013

Following a recommendation by an independent Data Monitoring Committee, US HIV/AIDS drug major Gilead…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Positive Ph II results for Gilead's idelalisib in refractory indolent non-Hodgkin's lymphoma

17-06-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) today (June 17) announced encouraging interim results…

BiotechnologyGilead SciencesidelalisibOncologyResearch

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program

03-05-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24-04-2013

Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Enrollment in Gilead's ION-1 study continues following planned DSMB review

26-03-2013

US HIV/AIDS and antiviral drugs specialist Gilead Sciences (Nasdaq: GILD) has provided a positive update…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvir

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

11-03-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

AHF demands FDA reversal on use of Gilead's HIV prevention pill for women

06-03-2013

Citing another failed clinical trial in women of the use of Gilead Sciences' (Nasdaq: GILD) AIDS drug…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationResearchTruvada

Gilead rises as sofosbuvir meets endpoints in Ph III hepatitis C study

20-02-2013

US AID/HIV drug giant Gilead Sciences (Nasdaq: GILD) saw its shares rise 2.5% to $42.60 in morning trading…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

Positive results from two Ph III Studies of Gilead's sofosbuvir for hepatitis C

05-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has revealed positive top-line results from two Phase…

Anti-viralsBiotechnologyGilead SciencesResearchsofosbuvir

1 to 25 of 38 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top